Reversible posterior leukoencephalopathy syndrome induced by axitinib

Antonin Levy; Lyes Benmoussa; Samy Ammari; Laurence Albiges; Bernard Escudier

doi:10.1016/j.clgc.2013.08.008

Reversible posterior leukoencephalopathy syndrome induced by axitinib

Clin Genitourin Cancer. 2014 Feb;12(1):e33-4. doi: 10.1016/j.clgc.2013.08.008. Epub 2013 Oct 14.

Authors

Antonin Levy¹, Lyes Benmoussa¹, Samy Ammari², Laurence Albiges¹, Bernard Escudier³

Affiliations

¹ Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France.
² Department of Radiology, Gustave Roussy Institute, Paris XI University, Villejuif, France.
³ Department of Medical Oncology, Gustave Roussy Institute, Paris XI University, Villejuif, France. Electronic address: [email protected].

PMID: 24135633
DOI: 10.1016/j.clgc.2013.08.008

No abstract available

Keywords: Axitinib; Clear-cell renal adenocarcinoma; Reversible posterior leukoencephalopathy syndrome; Side-effect; Vascular endothelial growth factor.

Publication types

Case Reports

MeSH terms

Axitinib
Carcinoma, Renal Cell / drug therapy*
Female
Humans
Imidazoles / adverse effects*
Imidazoles / therapeutic use
Indazoles / adverse effects*
Indazoles / therapeutic use
Kidney Neoplasms / drug therapy*
Middle Aged
Posterior Leukoencephalopathy Syndrome / chemically induced*
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Receptors, Platelet-Derived Growth Factor / antagonists & inhibitors
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors

Substances

Imidazoles
Indazoles
Protein Kinase Inhibitors
Axitinib
Receptors, Platelet-Derived Growth Factor
Receptors, Vascular Endothelial Growth Factor